A detailed history of Caption Management, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Caption Management, LLC holds 8,200 shares of SAGE stock, worth $46,986. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,200
Previous 30,000 72.67%
Holding current value
$46,986
Previous $562,000 84.16%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$10.58 - $17.9 $46,446 - $78,581
-4,390 Reduced 89.78%
500 $5,000
Q1 2024

May 15, 2024

BUY
$18.62 - $26.95 $33,888 - $49,049
1,820 Added 59.28%
4,890 $91,000
Q4 2023

Feb 14, 2024

SELL
$17.1 - $22.26 $321,480 - $418,488
-18,800 Reduced 85.96%
3,070 $66,000
Q3 2023

Nov 14, 2023

BUY
$16.75 - $48.98 $366,322 - $1.07 Million
21,870 New
21,870 $450,000
Q2 2022

Aug 15, 2022

SELL
$27.52 - $37.99 $1.65 Million - $2.28 Million
-59,935 Reduced 93.22%
4,362 $141,000
Q1 2022

May 13, 2022

SELL
$30.71 - $45.71 $71,370 - $106,230
-2,324 Reduced 3.49%
64,297 $2.13 Million
Q4 2021

Feb 11, 2022

SELL
$37.06 - $47.11 $2.7 Million - $3.44 Million
-72,979 Reduced 52.28%
66,621 $2.84 Million
Q2 2021

Aug 16, 2021

BUY
$54.88 - $79.29 $7.07 Million - $10.2 Million
128,770 Added 1189.01%
139,600 $7.93 Million
Q1 2021

May 17, 2021

SELL
$70.65 - $96.76 $3.85 Million - $5.27 Million
-54,470 Reduced 83.42%
10,830 $810,000
Q4 2019

Feb 13, 2020

BUY
$60.18 - $154.77 $1.49 Million - $3.82 Million
24,700 Added 60.84%
65,300 $4.72 Million
Q1 2019

May 14, 2019

BUY
$89.33 - $163.65 $1.59 Million - $2.9 Million
17,750 Added 77.68%
40,600 $6.46 Million
Q4 2018

Jan 30, 2019

BUY
$81.94 - $139.71 $1.87 Million - $3.19 Million
22,850 New
22,850 $2.19 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $340M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.